Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Vaccine-Associated Anaphylaxis.

McNeil MM.

Curr Treat Options Allergy. 2019 Sep;6(3):297-308. doi: 10.1007/s40521-019-00215-0. Epub 2019 Jul 16.

PMID:
31815089
2.

The use of natural language processing to identify vaccine-related anaphylaxis at five health care systems in the Vaccine Safety Datalink.

Yu W, Zheng C, Xie F, Chen W, Mercado C, Sy LS, Qian L, Glenn S, Tseng HF, Lee G, Duffy J, McNeil MM, Daley MF, Crane B, McLean HQ, Jackson LA, Jacobsen SJ.

Pharmacoepidemiol Drug Saf. 2019 Dec 3. doi: 10.1002/pds.4919. [Epub ahead of print]

PMID:
31797475
3.

Challenges in evaluating post-licensure vaccine safety: observations from the Centers for Disease Control and Prevention.

Moro PL, Haber P, McNeil MM.

Expert Rev Vaccines. 2019 Oct;18(10):1091-1101. doi: 10.1080/14760584.2019.1676154. Epub 2019 Oct 19.

PMID:
31580725
4.

Adverse events following adenovirus type 4 and type 7 vaccine, live, oral in the Vaccine Adverse Event Reporting System (VAERS), United States, October 2011-July 2018.

McNeil MM, Paradowska-Stankiewicz I, Miller ER, Marquez PL, Seshadri S, Collins LC Jr, Cano MV.

Vaccine. 2019 Oct 16;37(44):6760-6767. doi: 10.1016/j.vaccine.2019.08.087. Epub 2019 Sep 20.

PMID:
31548014
5.

Sociodemographic and clinical correlates of human papillomavirus vaccine attitudes and receipt among Wisconsin adolescents.

Hanson KE, McLean HQ, Belongia EA, Stokley S, McNeil MM, Gee J, VanWormer JJ.

Papillomavirus Res. 2019 Dec;8:100168. doi: 10.1016/j.pvr.2019.05.001. Epub 2019 May 25.

6.

Afamelanotide in the Treatment of Dermatologic Disease

McNeil MM, Nahhas AF, Braunberger TL, Hamzavi IH.

Skin Therapy Lett. 2018 Nov;23(6):6-10.

7.

Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines.

Kochhar S, Excler JL, Bok K, Gurwith M, McNeil MM, Seligman SJ, Khuri-Bulos N, Klug B, Laderoute M, Robertson JS, Singh V, Chen RT; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine. 2019 Sep 10;37(38):5796-5802. doi: 10.1016/j.vaccine.2018.08.085. Epub 2018 Nov 26.

8.

Vaccination and risk of lone atrial fibrillation in the active component United States military.

McNeil MM, Duderstadt SK, Sabatier JF, Ma GG, Duffy J.

Hum Vaccin Immunother. 2019;15(3):669-676. doi: 10.1080/21645515.2018.1549453. Epub 2019 Jan 8.

PMID:
30444675
9.

Cluster anxiety-related adverse events following immunization (AEFI): An assessment of reports detected in social media and those identified using an online search engine.

Suragh TA, Lamprianou S, MacDonald NE, Loharikar AR, Balakrishnan MR, Benes O, Hyde TB, McNeil MM.

Vaccine. 2018 Sep 25;36(40):5949-5954. doi: 10.1016/j.vaccine.2018.08.064. Epub 2018 Aug 29. Review.

10.

Reports of lower respiratory tract infection following dose 1 of RotaTeq and Rotarix vaccines to the Vaccine Adverse Event Reporting System (VAERS), 2008-2016.

Haber P, Amin M, Ng C, Weintraub E, McNeil MM.

Hum Vaccin Immunother. 2018;14(11):2755-2759. doi: 10.1080/21645515.2018.1491509. Epub 2018 Jul 26.

11.

Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.

Jackson ML, Yu O, Nelson JC, Nordin JD, Tartof SY, Klein NP, Donahue JG, Irving SA, Glanz JM, McNeil MM, Jackson LA.

Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):921-925. doi: 10.1002/pds.4569. Epub 2018 Jun 3.

12.

Assessing Potential Confounding and Misclassification Bias When Studying the Safety of the Childhood Immunization Schedule.

Daley MF, Shoup JA, Newcomer SR, Jackson ML, Groom HC, Jacobsen SJ, McLean HQ, Klein NP, Weintraub ES, McNeil MM, Glanz JM.

Acad Pediatr. 2018 Sep - Oct;18(7):754-762. doi: 10.1016/j.acap.2018.03.007. Epub 2018 Mar 28.

13.

Vaccination Patterns in Children After Autism Spectrum Disorder Diagnosis and in Their Younger Siblings.

Zerbo O, Modaressi S, Goddard K, Lewis E, Fireman BH, Daley MF, Irving SA, Jackson LA, Donahue JG, Qian L, Getahun D, DeStefano F, McNeil MM, Klein NP.

JAMA Pediatr. 2018 May 1;172(5):469-475. doi: 10.1001/jamapediatrics.2018.0082.

14.

Human Papillomavirus Vaccine Coverage and Prevalence of Missed Opportunities for Vaccination in an Integrated Healthcare System.

Irving SA, Groom HC, Stokley S, McNeil MM, Gee J, Smith N, Naleway AL.

Acad Pediatr. 2018 Mar;18(2S):S85-S92. doi: 10.1016/j.acap.2017.09.002.

15.

Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method.

Li R, Weintraub E, McNeil MM, Kulldorff M, Lewis EM, Nelson J, Xu S, Qian L, Klein NP, Destefano F.

Pharmacoepidemiol Drug Saf. 2018 Apr;27(4):391-397. doi: 10.1002/pds.4397. Epub 2018 Feb 15.

PMID:
29446176
16.

Vaccine-associated hypersensitivity.

McNeil MM, DeStefano F.

J Allergy Clin Immunol. 2018 Feb;141(2):463-472. doi: 10.1016/j.jaci.2017.12.971. Review.

17.

Notes from the Field: Errors in Administration of an Excess Dosage of Yellow Fever Vaccine - United States, 2017.

McNeil MM, Hibbs BF, Miller ER, Cano MV.

MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):109-110. doi: 10.15585/mmwr.mm6703a6. No abstract available.

18.

Reply to Burgner, et al.

Bardenheier BH, McNeil MM, Wodi AP, McNicholl JM, DeStefano F.

Clin Infect Dis. 2018 Jan 6;66(2):319. doi: 10.1093/cid/cix839. No abstract available.

19.

Anxiety-related adverse events following immunization (AEFI): A systematic review of published clusters of illness.

Loharikar A, Suragh TA, MacDonald NE, Balakrishnan MR, Benes O, Lamprianou S, Hyde TB, McNeil MM.

Vaccine. 2018 Jan 4;36(2):299-305. doi: 10.1016/j.vaccine.2017.11.017. Epub 2017 Nov 29. Review.

PMID:
29198916
20.

Association between parent attitudes and receipt of human papillomavirus vaccine in adolescents.

VanWormer JJ, Bendixsen CG, Vickers ER, Stokley S, McNeil MM, Gee J, Belongia EA, McLean HQ.

BMC Public Health. 2017 Oct 2;17(1):766. doi: 10.1186/s12889-017-4787-5.

21.

Current safety issues with quadrivalent meningococcal conjugate vaccines.

Myers TR, McNeil MM.

Hum Vaccin Immunother. 2018 May 4;14(5):1175-1178. doi: 10.1080/21645515.2017.1366393. Epub 2017 Nov 8. Review.

22.

Risk of Nontargeted Infectious Disease Hospitalizations Among US Children Following Inactivated and Live Vaccines, 2005-2014.

Bardenheier BH, McNeil MM, Wodi AP, McNicholl JM, DeStefano F.

Clin Infect Dis. 2017 Sep 1;65(5):729-737. doi: 10.1093/cid/cix442.

23.

Improving Human Papillomavirus Vaccine Use in an Integrated Health System: Impact of a Provider and Staff Intervention.

McLean HQ, VanWormer JJ, Chow BDW, Birchmeier B, Vickers E, DeVries E, Meyer J, Moore J, McNeil MM, Stokley S, Gee J, Belongia EA.

J Adolesc Health. 2017 Aug;61(2):252-258. doi: 10.1016/j.jadohealth.2017.02.019. Epub 2017 Apr 24.

24.

Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule.

Daley MF, Glanz JM, Newcomer SR, Jackson ML, Groom HC, Lugg MM, McLean HQ, Klein NP, Weintraub ES, McNeil MM.

Vaccine. 2017 Apr 4;35(15):1873-1878. doi: 10.1016/j.vaccine.2017.02.058. Epub 2017 Mar 9.

25.

Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo®) reported to the Vaccine Adverse Event Reporting system (VAERS), 2010-2015.

Myers TR, McNeil MM, Ng CS, Li R, Lewis PW, Cano MV.

Vaccine. 2017 Mar 27;35(14):1758-1763. doi: 10.1016/j.vaccine.2017.02.030. Epub 2017 Mar 3.

26.

Vaccine adverse events in a safety net healthcare system and a managed care organization.

Narwaney KJ, Breslin K, Ross CA, Shoup JA, Wain KF, Weintraub ES, McNeil MM, Hambidge SJ.

Vaccine. 2017 Mar 1;35(9):1335-1340. doi: 10.1016/j.vaccine.2017.01.017. Epub 2017 Feb 6.

27.

Integration of data from a safety net health care system into the Vaccine Safety Datalink.

Hambidge SJ, Ross C, Shoup JA, Wain K, Narwaney K, Breslin K, Weintraub ES, McNeil MM.

Vaccine. 2017 Mar 1;35(9):1329-1334. doi: 10.1016/j.vaccine.2017.01.027. Epub 2017 Feb 1.

28.

Anthrax Vaccine and the Risk of Rheumatoid Arthritis and Systemic Lupus Erythematosus in the U.S. Military: A Case-Control Study.

Bardenheier BH, Duffy J, Duderstadt SK, Higgs JB, Keith MP, Papadopoulos PJ, Gilliland WR, McNeil MM.

Mil Med. 2016 Oct;181(10):1348-1356.

30.

Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasons.

Li R, Stewart B, McNeil MM, Duffy J, Nelson J, Kawai AT, Baxter R, Belongia EA, Weintraub E.

Pharmacoepidemiol Drug Saf. 2016 Aug;25(8):928-34. doi: 10.1002/pds.3996. Epub 2016 Apr 1.

PMID:
27037540
31.

Recent developments in the understanding and use of anthrax vaccine adsorbed: achieving more with less.

Schiffer JM, McNeil MM, Quinn CP.

Expert Rev Vaccines. 2016 Sep;15(9):1151-62. doi: 10.1586/14760584.2016.1162104. Epub 2016 Mar 25. Review.

PMID:
26942655
32.

Vaccination and 30-Day Mortality Risk in Children, Adolescents, and Young Adults.

McCarthy NL, Gee J, Sukumaran L, Weintraub E, Duffy J, Kharbanda EO, Baxter R, Irving S, King J, Daley MF, Hechter R, McNeil MM.

Pediatrics. 2016 Mar;137(3):e20152970. doi: 10.1542/peds.2015-2970. Epub 2016 Feb 1.

33.

Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations.

Sukumaran L, McCarthy NL, Kharbanda EO, McNeil MM, Naleway AL, Klein NP, Jackson ML, Hambidge SJ, Lugg MM, Li R, Weintraub ES, Bednarczyk RA, King JP, DeStefano F, Orenstein WA, Omer SB.

JAMA. 2015 Oct 20;314(15):1581-7. doi: 10.1001/jama.2015.12790.

34.

Risk of anaphylaxis after vaccination in children and adults.

McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ, Klein NP, Hambidge SJ, Lee GM, Jackson LA, Irving SA, King JP, Kharbanda EO, Bednarczyk RA, DeStefano F.

J Allergy Clin Immunol. 2016 Mar;137(3):868-78. doi: 10.1016/j.jaci.2015.07.048. Epub 2015 Oct 6.

35.

Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis and Influenza Vaccinations in Pregnancy.

Sukumaran L, McCarthy NL, Kharbanda EO, Weintraub ES, Vazquez-Benitez G, McNeil MM, Li R, Klein NP, Hambidge SJ, Naleway AL, Lugg MM, Jackson ML, King JP, DeStefano F, Omer SB, Orenstein WA.

Obstet Gynecol. 2015 Nov;126(5):1069-74. doi: 10.1097/AOG.0000000000001066.

36.

The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States.

Moro PL, McNeil MM, Sukumaran L, Broder KR.

Hum Vaccin Immunother. 2015;11(12):2872-9. doi: 10.1080/21645515.2015.1072664. Epub 2015 Sep 17.

37.

Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013.

Sukumaran L, McNeil MM, Moro PL, Lewis PW, Winiecki SK, Shimabukuro TT.

Clin Infect Dis. 2015 May 15;60(10):e58-65. doi: 10.1093/cid/civ061. Epub 2015 Jan 30.

38.

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.

Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22.

PMID:
25258101
39.

The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety.

McNeil MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, Jackson LA, Omer SB, Jacobsen SJ, DeStefano F.

Vaccine. 2014 Sep 22;32(42):5390-8. doi: 10.1016/j.vaccine.2014.07.073. Epub 2014 Aug 6. Review.

40.

Ischemic cardiac events and other adverse events following ACAM2000(®) smallpox vaccine in the Vaccine Adverse Event Reporting System.

McNeil MM, Cano M, R Miller E, Petersen BW, Engler RJ, Bryant-Genevier MG.

Vaccine. 2014 Aug 20;32(37):4758-65. doi: 10.1016/j.vaccine.2014.06.034. Epub 2014 Jun 18.

41.

Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial.

Pondo T, Rose CE Jr, Martin SW, Keitel WA, Keyserling HL, Babcock J, Parker S, Jacobson RM, Poland GA, McNeil MM.

Vaccine. 2014 Jun 12;32(28):3548-54. doi: 10.1016/j.vaccine.2014.04.025. Epub 2014 Apr 24.

42.

Continuous sequential boundaries for vaccine safety surveillance.

Li R, Stewart B, Weintraub E, McNeil MM.

Stat Med. 2014 Aug 30;33(19):3387-97. doi: 10.1002/sim.6161. Epub 2014 Apr 1.

PMID:
24691986
43.

Military healthcare providers reporting of adverse events following immunizations to the vaccine adverse event reporting system.

Li R, McNeil MM, Pickering S, Pemberton MR, Duran LL, Collins LC, Nelson MR, Engler RJ.

Mil Med. 2014 Apr;179(4):435-41. doi: 10.7205/MILMED-D-13-00391.

44.

Assessing agreement of repeated binary measurements with an application to the CDC's anthrax vaccine clinical trial.

Pan Y, Rose CE, Haber M, Ma Y, Carrasco JL, Stewart B, Keitel WA, Keyserling H, Jacobson RM, Poland G, McNeil MM.

Int J Biostat. 2013 Jul 27;9(1). pii: /j/ijb.2013.9.issue-1/ijb-2012-0001/ijb-2012-0001.xml. doi: 10.1515/ijb-2012-0001.

45.

Who is unlikely to report adverse events after vaccinations to the Vaccine Adverse Event Reporting System (VAERS)?

McNeil MM, Li R, Pickering S, Real TM, Smith PJ, Pemberton MR.

Vaccine. 2013 May 31;31(24):2673-9. doi: 10.1016/j.vaccine.2013.04.009. Epub 2013 Apr 16.

PMID:
23597717
46.

Health-related quality of life in the CDC Anthrax Vaccine Adsorbed Human Clinical Trial.

Stewart B, Rose CE, Tokars JI, Martin SW, Keitel WA, Keyserling HL, Babcock J, Parker SD, Jacobson RM, Poland GA, McNeil MM.

Vaccine. 2012 Aug 31;30(40):5875-9. doi: 10.1016/j.vaccine.2012.06.076. Epub 2012 Jul 17.

47.

A cluster of nonspecific adverse events in a military reserve unit following pandemic influenza A (H1N1) 2009 vaccination-possible stimulated reporting?

McNeil MM, Arana J, Stewart B, Hartshorn M, Hrncir D, Wang H, Lamias M, Locke M, Stamper J, Tokars JI, Engler RJ.

Vaccine. 2012 Mar 23;30(14):2421-6. doi: 10.1016/j.vaccine.2012.01.072. Epub 2012 Feb 3.

PMID:
22310205
48.

Health-related quality of life in the Anthrax Vaccination Program for workers in the Laboratory Response Network.

Stewart B, Zhang Y, Rose CE Jr, Tokars JI, Martin SW, Franzke LH, McNeil MM.

Vaccine. 2012 Feb 27;30(10):1841-6. doi: 10.1016/j.vaccine.2011.12.128. Epub 2012 Jan 9.

PMID:
22230591
49.

Vaccination and risk of type 1 diabetes mellitus in active component U.S. Military, 2002-2008.

Duderstadt SK, Rose CE Jr, Real TM, Sabatier JF, Stewart B, Ma G, Yerubandi UD, Eick AA, Tokars JI, McNeil MM.

Vaccine. 2012 Jan 17;30(4):813-9. doi: 10.1016/j.vaccine.2011.10.087. Epub 2011 Nov 8.

PMID:
22075092
50.

Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.

Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, Lewis P, McNeil MM, Bryant M, Singleton J, Martin D, DeStefano F.

Vaccine. 2010 Oct 21;28(45):7248-55. doi: 10.1016/j.vaccine.2010.09.021. Epub 2010 Sep 16.

PMID:
20850534

Supplemental Content

Loading ...
Support Center